search
Back to results

Nabilone & Marijuana Addiction

Primary Purpose

Marijuana Smoking

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Cesemat
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Marijuana Smoking focused on measuring Efficacy, Marijuana, Reduction, Craving

Eligibility Criteria

19 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 19 years or older
  • History of marijuana use

Sites / Locations

  • Vancouver General Hospital - Psychiatry Outpatient

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Cesemat

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Safety and tolerability to Nabilone

Secondary Outcome Measures

Marijuana craving questionnaire

Full Information

First Posted
December 2, 2009
Last Updated
February 16, 2011
Sponsor
University of British Columbia
search

1. Study Identification

Unique Protocol Identification Number
NCT01025700
Brief Title
Nabilone & Marijuana Addiction
Official Title
A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of British Columbia

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Safety of Nabilone in reducing marijuana craving
Detailed Description
Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Marijuana Smoking
Keywords
Efficacy, Marijuana, Reduction, Craving

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cesemat
Arm Type
Experimental
Arm Title
Placebo
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
Cesemat
Other Intervention Name(s)
Nabilone
Intervention Description
1 mg capsule per day for 21 days
Primary Outcome Measure Information:
Title
Safety and tolerability to Nabilone
Secondary Outcome Measure Information:
Title
Marijuana craving questionnaire

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 19 years or older History of marijuana use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shaohua Lu, MD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vancouver General Hospital - Psychiatry Outpatient
City
Vancouver
State/Province
British Columbia
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Nabilone & Marijuana Addiction

We'll reach out to this number within 24 hrs